[Efficacy of anti-cytokines and anti-RANKL antibody for treatment of RA and osteoporosis].
Rheumatoid arthritis (RA) is characterized by inflammatory synovitis, erosive arthritis and joint destruction. Recent evidence indicates that inflammatory cytokines such as TNF-alpha or IL-6 plays a pathological role in joint destruction and osteoporosis and that anti-cytokine therapy or anti-RANKL antibody provides significant protection against the process.
Okada
Yosuke
Y
University of Occupational and Environmental Health, School of Medicine, The First Department of Internal Medicine.
Nawata
Masao
M
Tanaka
Yoshiya
Y
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000209:etiology; D000069448:Denosumab; D006801:Humans; D018836:Inflammation Mediators / Q000276:immunology* / Q000502:physiology; D000069285:Infliximab; D015850:Interleukin-6 / Q000276:immunology* / Q000502:physiology; D010024:Osteoporosis / Q000188:drug therapy* / Q000209:etiology; D053245:RANK Ligand / Q000276:immunology* / Q000502:physiology / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology* / Q000502:physiology
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D018836:Inflammation Mediators; D015850:Interleukin-6; D053245:RANK Ligand; D014409:Tumor Necrosis Factor-alpha; D000069448:Denosumab; D000069285:Infliximab; C502936:tocilizumab